The evidence shows that patients receiving 15 mg/day of LMF for 30 days exhibited significantly greater reduction in Hamilton Depression Rating Scale (HDRS-17) scores and higher response rates compared to the placebo group. Additionally, a 12-month open extension trial indicated that 60% of initial non-responders eventually achieved remission with no serious adverse events.